Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI®

Slides:

Advertisements

Similar presentations

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV Erik De Clercq International Journal of Antimicrobial Agents Volume 33,

Advertisements

Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature.

Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis Giuseppe Valenza, Dennis Tappe, Doris.

Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times F.B. Spencker, L. Staber, T. Lietz,

Direct antimicrobial susceptibility testing method for analysis of sputum collected from patients with cystic fibrosis Mohamed Zebouh, Caroline Thomas,

Infections in Patients with Cystic Fibrosis

Population structure and characterization of viridans group streptococci (VGS) including Streptococcus pneumoniae isolated from adult patients with cystic.

Indicators of pulmonary exacerbation in cystic fibrosis: A Delphi survey of patients and health professionals Fiona McCourt, Brenda O'Neill, Ian Logan,

The immediate effect of musculoskeletal physiotherapy techniques and massage on pain and ease of breathing in adults with cystic fibrosis Annemarie Lee,

Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir

Development, validation, and implementation of a questionnaire assessing disease knowledge and understanding in adult cystic fibrosis patients Karen.

Cystic fibrosis research in allied health and nursing professions

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Amoxicillin–clavulanic acid resistance in fecal Enterobacteriaceae from patients with cystic fibrosis and healthy siblings Gwen Duytschaever, Geert Huys,

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Development of selective media for the isolation of yeasts and filamentous fungi from the sputum of adult patients with cystic fibrosis (CF) Yuriko Nagano,

Comparison of two pancreatic enzyme products for exocrine insufficiency in patients with cystic fibrosis C.J. Taylor, R. Thieroff-Ekerdt, S. Shiff, L.

Defining antimicrobial resistance in cystic fibrosis

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population Brandie D. Wagner, Frank J. Accurso,

Controlled clinical trials in cystic fibrosis — are we doing better?

Lucas R. Hoffman, Hemantha D. Kulasekara, Julia Emerson, Laura S

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Development of a novel PCR assay for the identification of the black yeast, Exophiala (Wangiella) dermatitidis from adult patients with cystic fibrosis.

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

The Journal of Cystic Fibrosis: Sunny perspectives

Vitamin A and lung function in CF

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Cystic fibrosis related diabetes in an extremely young patient

Inhalation solutions — Which ones may be mixed

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

Extensive diversification is a common feature of Pseudomonas aeruginosa populations during respiratory infections in cystic fibrosis Abdul Ashish, Steve.

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas.

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Nasal polyposis in lung transplant recipients with cystic fibrosis

Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions Gerard McCaughey,

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa Karen O. McKay, Peter J. Cooper, Peter P. van.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

Erythromycin improves gastric emptying half-time in adult cystic fibrosis patients with gastroparesis Adriano R. Tonelli, Walter E. Drane, Dennis P.

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis Giuseppe Valenza, Dennis Tappe, Doris.

Antibiograms of resistant Gram-negative bacteria from Scottish CF patients F.M. MacKenzie, S.V. Smith, K.E. Milne, K. Griffiths, J. Legge, I.M. Gould

CFTR modulators and pregnancy: Our work has only just begun

Patient segregation and aggressive antibiotic eradication therapy can control methicillin- resistant Staphylococcus aureus at large cystic fibrosis centres

Beta-lactam allergy in adults with cystic fibrosis

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity Henry J. Legere, Ross I. Palis, Tito Rodriguez.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis D.J. Touw, A.J. Knox,

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI® and BRAMITOB® (Tobramycin inhalation solutions) John E. Moore, Yasunori Maeda, Colin E. Goldsmith, Jacqueline C. Rendall, J. Stuart Elborn Journal of Cystic Fibrosis Volume 9, Issue 3, Pages 237-238 (May 2010) DOI: 10.1016/j.jcf.2010.03.005 Copyright © 2010 Elsevier B.V. Terms and Conditions

Fig. 1 Determination of the coefficient of correlation (r2) calculated from the paired comparison of the in vitro antimicrobial susceptibilities of TOBI® versus BRAMITOB® performed in triplicate in 100 wildtype CF P. aeruginosa isolates. For ease of visualisation, graph ends at MIC<6μg/ml, but r2 and F-values have been calculated based on all 100 isolates tested. Journal of Cystic Fibrosis 2010 9, 237-238DOI: (10.1016/j.jcf.2010.03.005) Copyright © 2010 Elsevier B.V. Terms and Conditions